NovoCure Limited

NasdaqGS:NVCR Stock Report

Market Cap: US$1.4b

NovoCure Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:NVCR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Sep 25BuyUS$996,859Ashley CordovaIndividual81,550US$12.22
29 Jul 25BuyUS$231,800Christoph BrackmannIndividual20,000US$11.63
03 Jun 25SellUS$17,269Allyson OceanIndividual999US$17.29
03 Jun 25SellUS$17,247Jeryl HillemanIndividual999US$17.26
03 Jun 25SellUS$17,299Timothy ScannellIndividual999US$17.32
03 Jun 25SellUS$17,259Kristin StaffordIndividual999US$17.28
03 Jun 25SellUS$17,176Martin MaddenIndividual999US$17.19
03 Jun 25SellUS$17,280David HungIndividual999US$17.30
03 Jun 25SellUS$17,329William VernonIndividual999US$17.35
03 Jun 25SellUS$17,297Kinyip LeungIndividual999US$17.31
03 May 25SellUS$10,604Mukund ParavasthuIndividual592US$17.91
03 Mar 25SellUS$4,634Mukund ParavasthuIndividual250US$18.54
03 Mar 25SellUS$38,055Ashley CordovaIndividual2,053US$18.54
03 Mar 25SellUS$5,071Uri WeinbergIndividual268US$18.92
03 Mar 25SellUS$46,841Frank LeonardIndividual2,527US$18.54
28 Feb 25SellUS$39,688Mukund ParavasthuIndividual2,014US$20.55
28 Feb 25SellUS$266,126Ashley CordovaIndividual13,494US$20.55
28 Feb 25SellUS$86,949Uri WeinbergIndividual4,637US$18.78
28 Feb 25SellUS$296,257Frank LeonardIndividual15,036US$20.55
27 Feb 25SellUS$19,844Nicolas LeupinIndividual991US$20.55
27 Feb 25SellUS$27,773Michael PuriIndividual1,387US$20.55
11 Jan 25SellUS$57,906Mukund ParavasthuIndividual2,160US$26.81
02 Nov 24SellUS$734Mukund ParavasthuIndividual44US$16.69
01 Nov 24SellUS$9,531Frank LeonardIndividual598US$15.94
01 Nov 24SellUS$2,540Mukund ParavasthuIndividual160US$15.88
31 Oct 24SellUS$12,792Michael PuriIndividual810US$15.79

Insider Trading Volume

Insider Buying: NVCR insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NVCR?
Owner TypeNumber of SharesOwnership Percentage
State or Government7,2410.00648%
General Public6,053,2805.41%
Hedge Funds6,904,3026.18%
Individual Insiders10,823,7749.68%
Institutions88,010,69378.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 78.89% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15%
FMR LLC
16,722,504US$212.9m1.43%0.01%
12.6%
BlackRock, Inc.
14,033,687US$178.6m8.39%no data
9.62%
The Vanguard Group, Inc.
10,752,396US$136.9m-4.44%no data
8.02%
Hansjoerg Wyss
8,967,046US$114.2m10.1%no data
6.18%
Soleus Capital Management, L.P.
6,904,302US$87.9m25.1%4.34%
5.71%
Capital Research and Management Company
6,382,848US$81.3m-54.9%no data
2.4%
State Street Global Advisors, Inc.
2,678,072US$34.1m3.45%no data
2.19%
Geode Capital Management, LLC
2,444,436US$31.1m-0.78%no data
2.03%
Balyasny Asset Management L.P.
2,270,076US$28.9m38.8%0.06%
1.47%
UBS Asset Management AG
1,644,913US$20.9m-24.7%no data
1.27%
Marshall Wace LLP
1,414,599US$18.0m-21.7%0.02%
1.22%
Quantinno Capital Management LP
1,368,663US$17.4m38.5%0.07%
1.16%
Renaissance Technologies LLC
1,300,054US$16.5m69.1%0.02%
1.02%
Point72 Asset Management, L.P.
1,140,900US$14.5m327%0.02%
1.02%
Northern Trust Global Investments
1,135,460US$14.5m-8.09%no data
1.01%
Baillie Gifford & Co.
1,128,652US$14.4m-0.73%0.01%
0.92%
American Century Investment Management Inc
1,029,874US$13.1m1,350%0.01%
0.9%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,009,040US$12.8m47.6%no data
0.86%
Palo Alto Investors LP
962,396US$12.3m-3.96%2.05%
0.81%
Charles Schwab Investment Management, Inc.
910,323US$11.6m11.2%no data
0.8%
Citadel Advisors LLC
894,148US$11.4m179%0.01%
0.74%
Deerfield Management Company, L.P.
825,119US$10.5m26.9%0.18%
0.74%
T. Rowe Price Group, Inc.
823,806US$10.5m70.9%no data
0.67%
Voloridge Investment Management, LLC
746,935US$9.5m2.89%0.03%
0.63%
Citigroup Inc.,Banking and Securities Investments
705,646US$9.0m733%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/12 19:38
End of Day Share Price 2025/09/12 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NovoCure Limited is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael KingCitizens JMP Securities, LLC
Gregory GilbertDeutsche Bank
Vijay KumarEvercore ISI